232 related articles for article (PubMed ID: 20531187)
41. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
[TBL] [Abstract][Full Text] [Related]
42. Survivin expression in ovarian cancer.
Liguang Z; Peishu L; Hongluan M; Hong J; Rong W; Wachtel MS; Frezza EE
Exp Oncol; 2007 Jun; 29(2):121-5. PubMed ID: 17704744
[TBL] [Abstract][Full Text] [Related]
43. Common epithelial tumors of borderline malignancy (carcinomas of low malignant potential).
Scully RE
Bull Cancer; 1982; 69(3):228-38. PubMed ID: 6289947
[TBL] [Abstract][Full Text] [Related]
44. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
[TBL] [Abstract][Full Text] [Related]
45. Epithelial ovarian tumors of borderline malignancy: long-term follow-up.
Casey AC; Bell DA; Lage JM; Fuller AF; Nikrui N; Rice LW
Gynecol Oncol; 1993 Sep; 50(3):316-22. PubMed ID: 8406194
[TBL] [Abstract][Full Text] [Related]
46. Epithelial ovarian tumors in adolescents: a retrospective pathologic study and a critical review of the literature.
Grapsa D; Kairi-Vassilatou E; Kleanthis C; Dastamani C; Fillipidou A; Kondi-Pafiti A
J Pediatr Adolesc Gynecol; 2011 Dec; 24(6):386-8. PubMed ID: 21945630
[TBL] [Abstract][Full Text] [Related]
47. Borderline tumors of the ovary and peritoneal implants.
Denkert C; Dietel M
Verh Dtsch Ges Pathol; 2005; 89():84-91. PubMed ID: 18035677
[TBL] [Abstract][Full Text] [Related]
48. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
49. Serous tumours of low malignant potential (serous borderline tumours): moving toward détente.
Longacre TA; Kempson RL; Hendrickson MR
Histopathology; 2005 Sep; 47(3):315-8. PubMed ID: 16115233
[No Abstract] [Full Text] [Related]
50. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
Hu YQ; Liu YJ
Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
[TBL] [Abstract][Full Text] [Related]
51. A huge ovarian mucinous cystadenoma in a 14-year-old premenarchal girl: review on ovarian mucinous tumor in premenarchal girls.
Karaman A; Azili MN; Boduroğlu EC; Karaman I; Erdoğan D; Cavuşoğlu YH; Aslan MK; Cakmak O
J Pediatr Adolesc Gynecol; 2008 Feb; 21(1):41-4. PubMed ID: 18312801
[TBL] [Abstract][Full Text] [Related]
52. Overview of the clinical problem: facts and current issues of mucinous cystic neoplasms of the pancreas.
Jeurnink SM; Vleggaar FP; Siersema PD
Dig Liver Dis; 2008 Nov; 40(11):837-46. PubMed ID: 18499541
[TBL] [Abstract][Full Text] [Related]
53. In vitro fertilization following conservative management of stage 3 serous borderline tumor of the ovary.
Hoffman JS; Laird L; Benadiva C; Dreiss R
Gynecol Oncol; 1999 Sep; 74(3):515-8. PubMed ID: 10479523
[TBL] [Abstract][Full Text] [Related]
54. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
[TBL] [Abstract][Full Text] [Related]
55. [Ovarian serous tumors of limited malignancy and invasive peritoneal implants. Review of the literature].
Fondrinier E; Seince N; Verriele V; Lorimier G; Gamelin E
Contracept Fertil Sex; 1999 Nov; 27(11):780-4. PubMed ID: 10609410
[TBL] [Abstract][Full Text] [Related]
56. Diagnosis and treatment of borderline ovarian neoplasms "the state of the art".
Tropé C; Davidson B; Paulsen T; Abeler VM; Kaern J
Eur J Gynaecol Oncol; 2009; 30(5):471-82. PubMed ID: 19899396
[TBL] [Abstract][Full Text] [Related]
57. Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: comparison with cystadenomas and overt carcinomas.
Darai E; Walker-Combrouze F; Fauconnier A; Madelenat P; Potet F; Scoazec JY
Histopathology; 1998 Feb; 32(2):151-9. PubMed ID: 9543672
[TBL] [Abstract][Full Text] [Related]
58. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary.
Griffiths AP; Cross D; Kingston RE; Harkin P; Wells M; Quirke P
Int J Gynecol Pathol; 1993 Oct; 12(4):307-14. PubMed ID: 8253547
[TBL] [Abstract][Full Text] [Related]
59. Prognostic significance of HLA-DR antigen in serous ovarian tumors.
Tamiolakis D; Kotini A; Venizelos J; Jivannakis T; Simopoulos C; Papadopoulos N
Clin Exp Med; 2003 Sep; 3(2):113-8. PubMed ID: 14598186
[TBL] [Abstract][Full Text] [Related]
60. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 May; 30(5):614-24. PubMed ID: 16699316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
